| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
26,020,000 |
| Market
Cap: |
199.83(M) |
| Last
Volume: |
6,675 |
Avg
Vol: |
6,626 |
| 52
Week Range: |
$5.01 - $9.88 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Home Health Care |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Fennec Pharmaceuticals is a biopharmaceutical company focused on the development of PEDMARK™ (sodium thiosulfate anhydrous injection) for the prevention of platinum-induced ototoxicity in pediatric cancer patients. Co. has licensed from Oregon Health & Science University intellectual property rights for the use of PEDMARK™ as a chemoprotectant and is developing PEDMARK™ as a protectant against the hearing loss caused by platinum-based anti-cancer agents in children.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
15,000 |
56,667 |
| Total Buy Value |
$0 |
$0 |
$104,601 |
$104,601 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
2 |
4 |
| Total Shares Sold |
1,354,248 |
1,375,367 |
1,464,629 |
1,905,317 |
| Total Sell Value |
$10,537,103 |
$10,716,949 |
$11,319,815 |
$15,052,477 |
| Total People Sold |
3 |
3 |
3 |
5 |
| Total Sell Transactions |
10 |
13 |
23 |
54 |
| End Date |
2025-10-05 |
2025-07-04 |
2025-01-03 |
2024-01-04 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Clark John Smith Ii |
10% Owner |
– – • |
2025-12-24 |
4 |
S |
$7.50 |
$7,500,000 |
I/I |
(1,000,000) |
2,744,741 |
|
-0% |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2025-12-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,430 |
175,534 |
|
- |
|
| Raykov Rosty |
|
– • – |
2025-12-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,208 |
87,526 |
|
- |
|
| Clark John Smith Ii |
10% Owner |
– – • |
2025-11-18 |
4 |
S |
$8.79 |
$170,048 |
I/I |
(19,341) |
3,744,741 |
|
12% |
|
| Clark John Smith Ii |
10% Owner |
– – • |
2025-11-17 |
4 |
S |
$8.79 |
$755,193 |
I/I |
(85,918) |
3,764,082 |
|
12% |
|
| Clark John Smith Ii |
10% Owner |
– – • |
2025-11-14 |
4 |
S |
$8.00 |
$1,280,432 |
I/I |
(160,100) |
3,850,000 |
|
2% |
|
| Raykov Rosty |
|
– • – |
2025-11-05 |
4 |
AS |
$8.10 |
$81,000 |
D/D |
(10,000) |
82,318 |
|
-7% |
|
| Raykov Rosty |
|
– • – |
2025-10-31 |
4 |
A |
$0.00 |
$0 |
D/D |
5,208 |
92,318 |
|
- |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2025-10-31 |
4 |
A |
$0.00 |
$0 |
D/D |
2,430 |
173,104 |
|
- |
|
| Rallis Chris A |
|
– • – |
2025-10-10 |
4 |
AS |
$9.24 |
$16,401 |
D/D |
(1,775) |
57,079 |
|
-10% |
|
| Rallis Chris A |
|
– • – |
2025-10-10 |
4 |
OE |
$1.23 |
$4,996 |
D/D |
4,062 |
58,854 |
|
- |
|
| Clark John Smith Ii |
10% Owner |
– – • |
2025-10-09 |
4 |
S |
$9.35 |
$192,614 |
I/I |
(20,609) |
4,010,100 |
|
17% |
|
| Clark John Smith Ii |
10% Owner |
– – • |
2025-10-08 |
4 |
S |
$9.47 |
$185,722 |
I/I |
(19,605) |
4,030,709 |
|
16% |
|
| Raykov Rosty |
|
– • – |
2025-10-08 |
4 |
OE |
$2.45 |
$11,292 |
D/D |
4,609 |
87,110 |
|
- |
|
| Clark John Smith Ii |
10% Owner |
– – • |
2025-10-07 |
4 |
S |
$9.59 |
$257,893 |
I/I |
(26,900) |
4,050,314 |
|
19% |
|
| Raykov Rosty |
|
– • – |
2025-10-06 |
4 |
AS |
$9.78 |
$97,800 |
D/D |
(10,000) |
82,501 |
|
-21% |
|
| Raykov Rosty |
|
– • – |
2025-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
5,208 |
92,501 |
|
- |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2025-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
2,430 |
170,674 |
|
- |
|
| Raykov Rosty |
|
– • – |
2025-09-05 |
4 |
OE |
$2.45 |
$88,707 |
D/D |
36,207 |
87,293 |
|
- |
|
| Raykov Rosty |
|
– • – |
2025-09-04 |
4 |
AS |
$8.92 |
$89,200 |
D/D |
(10,000) |
51,086 |
|
-16% |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2025-08-31 |
4 |
A |
$0.00 |
$0 |
D/D |
2,431 |
168,244 |
|
- |
|
| Raykov Rosty |
|
– • – |
2025-08-31 |
4 |
A |
$0.00 |
$0 |
D/D |
5,208 |
61,086 |
|
- |
|
| Raykov Rosty |
|
– • – |
2025-08-05 |
4 |
AS |
$8.09 |
$80,900 |
D/D |
(10,000) |
55,878 |
|
-8% |
|
| Raykov Rosty |
|
– • – |
2025-07-31 |
4 |
A |
$0.00 |
$0 |
D/D |
5,208 |
65,878 |
|
- |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2025-07-31 |
4 |
A |
$0.00 |
$0 |
D/D |
2,431 |
165,813 |
|
- |
|
274 Records found
|
|
Page 1 of 11 |
|
|
0.02 (0.26%) 
